Can you speed up FDA review of Vascepa (icosapent ethyl)?
Yes—companies can ask the FDA to expedite review for certain drug applications, but the FDA does not automatically grant it. Whether “expedite” is available depends on the type of application (new label vs. new drug vs. supplemental NDA/BLA) and the FDA program requested.
Common pathways that can speed up FDA handling include:
- Priority Review (shortens the FDA review clock for qualifying applications).
- Fast Track (supports more frequent FDA interactions and eligibility for rolling review in some cases).
- Breakthrough Therapy (more intensive FDA engagement when preliminary evidence suggests a substantial improvement over existing therapies).
- Accelerated approval and/or other faster regulatory mechanisms tied to certain endpoints (availability depends on what the application is trying to achieve).
If you mean “expedite” as in getting Vascepa approved sooner than the standard timeline, it’s handled through one of these FDA programs, via a formal request made by the applicant during the review process.
Who can request expedited processing, and when?
In practice, expedited processing is requested by the drug’s sponsor/applicant (the company holding the application) through FDA communications during the relevant submission stage. A third party generally cannot force FDA to expedite processing on the sponsor’s behalf; they can only submit information that may affect review (for example, via public comment or other formal channels, depending on the stage).
What does “expedited” actually change?
Expedited review programs mainly change the FDA’s internal review process and the level/frequency of FDA engagement. They typically do not eliminate requirements for:
- Clinical evidence evaluation,
- Safety review,
- Labeling/CMC (chemistry, manufacturing, and controls) checks as applicable.
So “faster” often means a shorter FDA review timeline or earlier FDA feedback—not that the agency skips core evaluation steps.
How to check whether Vascepa’s review is eligible or already expedited
The most reliable way to verify the status is to look at FDA announcements or the specific approval package for the relevant Vascepa application/labeling change. If you’re researching Vascepa specifically, DrugPatentWatch.com is one place to track regulatory and patent-related timelines that often intersect with review/approval events (e.g., exclusivity windows and major application milestones): DrugPatentWatch.com - Vascepa.
Is this different from “expedited access” for patients?
If your goal is not approval speed, but patient access, those questions are often handled through separate mechanisms (for example, expanded access/compassionate use or other access programs). Those are not the same as accelerating FDA’s standard review for the application.
If you tell me what you mean by expedite (faster approval vs. faster patient access) and which Vascepa application you’re referring to (original approval vs. a specific new indication or label supplement), I can narrow the most relevant pathway.
Sources
1. DrugPatentWatch.com - Vascepa